Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Recent News

SOHO 2021: Optimizing Treatment for Older Patients With AML
SOHO 2021: Novel Combination Therapy Under Study in Newly Diagnosed AML
SOHO 2021: Adding Azacitidine to FLAG Chemotherapy in AML
SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML
Is Chemotherapy Linked to Deterioration of Oral Health in Patients With AML?
One Man’s Experience With AML, COVID-19, and Allo-HSCT
Can Romyelocel-L Plus G-CSF Reduce Infections in Patients With AML?
Can MRD Guide Postremission Treatment Decisions in Intermediate-Risk AML?
Mixed Results Emerge in Phase II Selinexor Trial in Older Patients With Resistant AML
Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML
Japanese Subgroup Analysis of BCL2 Inhibitor Plus Low-Dose Cytarabine in Untreated AML
COVID-19 and Leukemias: Focus on Risk Factors for Poor Outcomes
Absolute Monocyte and Lymphocyte Counts in AML: Prognostic Significance at the Time of Relapse
Is the Presence of RUNX1 Mutations an Adverse Risk Factor in AML?
Anti-CD117 Monoclonal Antibody Plus Nonmyeloablative Conditioning in Older Patients With AML
FDA Brief: SNDX-5613 Receives Fast Track Designation for Certain Resistant Acute Leukemias
ASCO 2021: Exploring the Molecular Architecture of Extramedullary AML
EHA2021: Correlating MRD and Outcomes With Venetoclax and Azacitidine in AML
ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML
EHA2021: Venetoclax Plus Gilteritinib Under Study in Resistant FLT3-Mutated AML
ASCO 2021: Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy
EHA2021: Post Hoc Analysis of Oral Azacitidine in AML From QUAZAR AML-001 Trial
ASCO 2021: Novel FLT3 Inhibitor Under Study in Resistant AML
ASCO 2021: Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML
Australian Researchers Use Novel Work Utility Measure to Assess Productivity Impact of AML
Trousseau Syndrome and AML: Case Report
Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts
Quizartinib Combinations Under Study in FLT3-ITD–Mutated AML
Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers
Pilot Study in AML: Can Biomarkers Predict Chemotherapy-Related Infection?
Dactinomycin Under Study in Management of Resistant NPM1-Mutated AML
Have Outcomes in AML Improved Over the Past 40 Years?
CPX-351 for High-Risk AML: Phase III Post Hoc Analysis
AACR 2021: Daratumumab Plus Venetoclax Under Study in AML
Chemotherapy Intensity, MRD Status, and Outcomes in AML
AACR 2021: Is SIRT5 Enzyme Potential Therapeutic Target in AML?
Optimal Number of Chemotherapy Courses for Younger Patients With AML
Testing for Germline Mutations in Elderly Patients With AML
Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML
Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML
Predicting Response to Venetoclax Combination Therapy in Resistant AML
Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML
Case Report: Central Diabetes Insipidus and AML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.